Is Flavoxate registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Flavoxate, including GENURIN FORT 200 mg tablet (200 mg, Film-coated tablet, SAR 11.55).

Is Flavoxate approved by the US FDA?

Drugs@FDA lists 4 application product lines for Flavoxate, including FLAVOXATE HYDROCHLORIDE (Prescription); FLAVOXATE HYDROCHLORIDE (Prescription); URISPAS (Discontinued); FLAVOXATE HYDROCHLORIDE (Discontinued).

Active substance

Flavoxate

SFDA 2
US FDA 4
US price lines 1
NHS prices 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
GENURIN FORT 200 mg tablet	200 mg	Film-coated tablet · Oral use	30 Blister	SAR 11.55	NCE · Prescription	RECORDATI	Valid
GENURIN 100MG TAB	100 mg	Film-coated tablet · Oral use	30 Blister	SAR 8.50	NCE · Prescription	RECORDATI	Invalid · Not Marketed

Indications — CHI Daman Drug Formulary

BENIGN PROSTATIC HYPERTROPHY; NOCTURNAL ENURESIS; URINARY INCONTINENCE AND OVERACTIVE BLADDER

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
FLAVOXATE HYDROCHLORIDE	100MG	tablet · oral	PADAGIS US	Prescription	16 Dec 2004
FLAVOXATE HYDROCHLORIDE	100MG	tablet · oral	EPIC PHARMA	Prescription	30 Nov 2005
URISPAS	100MG	tablet · oral	ORTHO MCNEIL JANSSEN	Discontinued	15 Jan 1970
FLAVOXATE HYDROCHLORIDE	100MG	tablet · oral	IMPAX PHARMS	Discontinued	28 Aug 2003

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	FLAVOXATE HCL 100 MG TABLET	$0.3894	per EA	23 Sep 2026
NHS Drug Tariff	Flavoxate 200mg tablets	£11.67	90 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.